Hasan M, Mughees M, Shaikh S, Choudhary F, Nizam A, Rizwan A
Sensors (Basel). 2024; 24(18).
PMID: 39338894
PMC: 11435941.
DOI: 10.3390/s24186149.
Yousefi A, Sotoodehnejadnematalahi F, Nafissi N, Zeinali S, Azizi M
Sci Rep. 2024; 14(1):5845.
PMID: 38462658
PMC: 10925600.
DOI: 10.1038/s41598-024-56511-6.
Mohammadi M, Fazilat A, Mamalo A, Ojarudi M, Hemmati-Dinarvand M, Beilankouhi E
Mol Biol Rep. 2024; 51(1):221.
PMID: 38281224
DOI: 10.1007/s11033-023-09191-w.
Kurozumi S, Seki N, Narusawa E, Honda C, Tokuda S, Nakazawa Y
Int J Mol Sci. 2024; 25(1).
PMID: 38203206
PMC: 10779190.
DOI: 10.3390/ijms25010035.
Zuo Y, Ma M, Wen Y, Chang L, Qu C
Clin Transl Oncol. 2023; 25(7):2192-2203.
PMID: 36862282
DOI: 10.1007/s12094-023-03102-y.
MicroRNAs: A Link between Mammary Gland Development and Breast Cancer.
Wu D, Thompson L, Comelli E
Int J Mol Sci. 2022; 23(24).
PMID: 36555616
PMC: 9786715.
DOI: 10.3390/ijms232415978.
The Role of miRNA-182 and FOXO3 Expression in Breast Cancer.
Kandil N, Kandil L, Mohamed R, Selima M, El Nemr M, Barakat A
Asian Pac J Cancer Prev. 2022; 23(10):3361-3370.
PMID: 36308360
PMC: 9924337.
DOI: 10.31557/APJCP.2022.23.10.3361.
Prognostic value of 12 m7G methylation-related miRNA markers and their correlation with immune infiltration in breast cancer.
Zhang W, Zhang S, Wang Z
Front Oncol. 2022; 12:929363.
PMID: 35992830
PMC: 9389359.
DOI: 10.3389/fonc.2022.929363.
Blood Circulating Non-Coding RNAs for the Clinical Management of Triple-Negative Breast Cancer.
Powrozek T, Ochieng Otieno M
Cancers (Basel). 2022; 14(3).
PMID: 35159070
PMC: 8833777.
DOI: 10.3390/cancers14030803.
Differences in plasma microRNA content impair microRNA-based signature for breast cancer diagnosis in cohorts recruited from heterogeneous environmental sites.
Uyisenga J, Debit A, Poulet C, Freres P, Poncin A, Thiry J
Sci Rep. 2021; 11(1):11698.
PMID: 34083680
PMC: 8175697.
DOI: 10.1038/s41598-021-91278-0.
Plasma Circulating Mirnas Profiling for Identification of Potential Breast Cancer Early Detection Biomarkers.
Rashid Jusoh A, Mohan S, Lu Ping T, Tengku Din T, Haron J, Romli R
Asian Pac J Cancer Prev. 2021; 22(5):1375-1381.
PMID: 34048164
PMC: 8408402.
DOI: 10.31557/APJCP.2021.22.5.1375.
PMDFI: Predicting miRNA-Disease Associations Based on High-Order Feature Interaction.
Tang M, Liu C, Liu D, Liu J, Liu J, Deng L
Front Genet. 2021; 12:656107.
PMID: 33897768
PMC: 8063614.
DOI: 10.3389/fgene.2021.656107.
MiR-105-3p acts as an oncogene to promote the proliferation and metastasis of breast cancer cells by targeting GOLIM4.
Lin B, Liu C, Shi E, Jin Q, Zhao W, Wang J
BMC Cancer. 2021; 21(1):275.
PMID: 33722196
PMC: 7962220.
DOI: 10.1186/s12885-021-07909-2.
Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients.
Schlick K, Hohla F, Hamacher F, Hackl H, Hufnagl C, Markus S
Future Sci OA. 2021; 7(2):FSO644.
PMID: 33437513
PMC: 7787156.
DOI: 10.2144/fsoa-2020-0128.
Prognostic role of microRNA 182 and microRNA 18a in locally advanced triple negative breast cancer.
Bajaj R, Tripathi R, Sridhar T, Korlimarla A, Choudhury K, Suryavanshi M
PLoS One. 2020; 15(11):e0242190.
PMID: 33175907
PMC: 7657558.
DOI: 10.1371/journal.pone.0242190.
Circulating miRNAs in HER2-Positive and Triple Negative Breast Cancers: Potential Biomarkers and Therapeutic Targets.
Gupta I, Rizeq B, Vranic S, Moustafa A, Al Farsi H
Int J Mol Sci. 2020; 21(18).
PMID: 32942528
PMC: 7554858.
DOI: 10.3390/ijms21186750.
miR-622 is a novel potential biomarker of breast carcinoma and impairs motility of breast cancer cells through targeting NUAK1 kinase.
Orlandella F, Mariniello R, Mirabelli P, De Stefano A, Iervolino P, Lasorsa V
Br J Cancer. 2020; 123(3):426-437.
PMID: 32418991
PMC: 7403386.
DOI: 10.1038/s41416-020-0884-9.
Integrative analysis of DNA methylation and gene expression profiles identified potential breast cancer-specific diagnostic markers.
Liu X, Peng Y, Wang J
Biosci Rep. 2020; 40(5).
PMID: 32412047
PMC: 7263199.
DOI: 10.1042/BSR20201053.
MiR-33a functions as a tumor suppressor in triple-negative breast cancer by targeting EZH2.
Weihua Z, Guorong Z, Xiaolong C, Weizhan L
Cancer Cell Int. 2020; 20:85.
PMID: 32206036
PMC: 7079399.
DOI: 10.1186/s12935-020-1160-z.
Circulating MicroRNAs and Blood-Brain-Barrier Function in Breast Cancer Metastasis.
Curtaz C, Schmitt C, Blecharz-Lang K, Roewer N, Wockel A, Burek M
Curr Pharm Des. 2020; 26(13):1417-1427.
PMID: 32175838
PMC: 7475800.
DOI: 10.2174/1381612826666200316151720.